A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors
These results indicate tolerability and potential antitumor activity when combining anti-CD47 therapy and cetuximab in heavily pretreated patients with CRC.
Authors
- Yeon‐Ju Lee (ORCID: https://orcid.org/0000-0003-4814-943X)
- Nehal J. Lakhani (ORCID: https://orcid.org/0009-0005-6327-0176)
- Cathy Eng (ORCID: https://orcid.org/0000-0003-2335-0612)
- Benny Johnson (ORCID: https://orcid.org/0000-0003-3683-8115)
- Philip A. Philip (ORCID: https://orcid.org/0000-0002-6513-3491)
- George A. Fisher (ORCID: https://orcid.org/0000-0002-6828-3938)
- Adel Kardosh
- Denise Jin
- Charles Schneider (ORCID: https://orcid.org/0000-0002-3768-8473)
- Yanan Huo (ORCID: https://orcid.org/0000-0002-4541-9791)
- Michael F. Howland (ORCID: https://orcid.org/0000-0002-2878-3874)
- Amita Patnaik (ORCID: https://orcid.org/0000-0002-4144-2193)
- Mark P. Chao (ORCID: https://orcid.org/0000-0002-5842-7272)
- Kai Song (ORCID: https://orcid.org/0000-0001-6792-7159)
- F. Shihadeh
- J. Randolph Hecht
Institutions
- SRI International (US)
- Van Andel Institute (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of California, Los Angeles (US)
- Oregon Health & Science University (US)
- The Barbara Ann Karmanos Cancer Institute (US)
- South Texas Accelerated Research Therapeutics (US)
- Gilead Sciences (United States) (US)
- Center for Cancer Research (US)
- University of Pennsylvania (US)
- Stanford University (US)
Publication Details
- Journal
- Targeted Oncology
- Published
- 2025-03-26
- DOI
- https://doi.org/10.1007/s11523-025-01130-y
- Citations
- 11
- Primary Topic
- Phagocytosis and Immune Regulation
- Type
- article
- Field-Weighted Citation Impact
- 8.77
Funders
- Gilead Sciences